Zimbabwe has declined a major US health deal worth $367m (£272m) over five years due to Washington's request for sensitive data.
This move came to light after a internal memorandum dated December was leaked, which showed Head of State Emmerson Mnangagwa believed the arrangement was "skewed".
A government representative later clarified that the United States was demanding access to health data for research and commercial purposes while was unwilling to guarantee the benefits from any future treatments.
"We must now begin the challenging and unfortunate process of ending our support in Zimbabwe," stated US ambassador to Zimbabwe Pamela Tremont publicly.
Her embassy noted the US had donated more than $1.9bn as health assistance to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged further negotiations to find a agreement acceptable to all parties so the nation's vital HIV treatment initiative can be sustained.
Broader Background
This development comes after a comparable case in neighbouring Kenya, where a court suspended a related health funding agreement following legal challenges were filed about the safety of citizens' health data.
After returning to the presidency recently, US President Donald Trump has reduced foreign aid and shut down the US Agency for International Development (USAID).
USAID had administered assistance for the American government, but Trump stated its expenditure was "inefficient" and his administration was seeking direct bilateral deals to boost transparency and accountability.
According to reports, Sixteen nations in Africa have so far signed similar agreements, constituting more than $18.3bn of fresh investment.
Specifics of the Declined Deal
The money for Zimbabwe would have funded "combating HIV/Aids, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"We are confident this cooperation might have yielded immense benefits for the people of Zimbabwe, especially the 1.2 million presently receiving HIV treatment through American-funded initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "unequal".
"The proposal required Zimbabwe to share its biological resources and data indefinitely, without any equivalent assurance of access to any medical innovations – such as new medicines or tests – that might be developed from that shared data," his statement read.
"In essence, our nation would provide the basic resources for scientific discovery with no assurance that the final treatments would be available to our population if a new disease outbreak emerge."
National Interest and Global Health
Mangwana further noted that the US's withdrawal from the World Health Organization (WHO) and its pursuit of one-on-one health agreements were disrupting frameworks already set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing scheme created to deal with potential global health emergencies.
"This framework is intended to ensure that when a nation contributes its samples, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the resources to create them."
Zimbabwe's reservations regarding the US deal "should not be misconstrued as hostility towards the US," he added.
"We are open to continued dialogue with our US partners on how subsequent co-operation could be structured in a way that respects the sovereignty and dignity of both nations."
Health Experts Response
Medical experts said it recognised the official position, but urged that talks should continue since much of the country's Aids initiatives relied on external financing.
"In cases where specific concerns arise, such as those involving data governance or agreement terms, these can frequently be addressed through detailed discussion and mutually agreed protections," the group said.
The halted deal highlights the continuing challenges between receiving crucial international aid and safeguarding a country's data in an ever more interconnected world.